Previous close | N/A |
Open | 74.85 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 74.85 - 74.85 |
52-week range | 74.85 - 74.85 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 13.40 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
RAHWAY, N.J., June 27, 2022--LYNPARZA® Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
RAHWAY, N.J., June 24, 2022--European Commission Approves KEYTRUDA as Adjuvant Treatment for Adult & Adolescent Patients With Stage IIB or IIC Melanoma After Complete Resection
RAHWAY, N.J., June 22, 2022--CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ as an Option for Pneumococcal Vaccination in Infants and Children